(Press-News.org) HOUSTON - In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in December 2012 at the 54th American Society of Hematology Annual Meeting and Exposition.
Unprecedented results, fewer side effects
"This oral inhibitor of the Bruton's tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. Wang is lead author of the trial.
"It is an oral drug, taken once a day, and its side effects are not severe. Yet it can achieve more than previous combination chemotherapy approaches. Our results constitute excellent news for our patients and patients around the world."
The ongoing trial of oral ibrutinib in patients with heavily treated relapsed or refractory MCL has maintained a response rate as high as 70 percent - better than any other single agent ever tested in the challenging disease – with milder side effects than other treatments.
Targeted approach to dangerous disease
MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. Despite high response rates to initial highly toxic combination-drug chemotherapy, patients often relapse.
The B-cell receptor pathway is critical in B-cell lymphoma, and Bruton's tyrosine kinase (BTK) is an essential component of this pathway. Ibrutinib targets the BTK molecule, causing cell death and decreasing cellular migration and adhesion in malignant B-cells.
In this study, patients were given 560 mg daily ibrutinib in continuous 28-day cycles until disease progressed or side effects became intolerable. To date, 111 patients have participated in the study.
Seventy-seven percent had stage 4 disease, and the median number of prior treatments was three.
Ongoing results continue to show promise
In the past six months, ibrutinib has continued to show excellent results. With a median follow-up period of 15 months:
Overall response rate was 68 percent
Complete response rate was 21 percent
Partial response rate 47 percent
Response and complete remission rates improved with longer duration of treatment.
Among the 75 patients who responded, median:
Response duration was 18 months
Time to response was two months
Progression-free survival was 14 months
Most side effects were minor and included diarrhea, fatigue, upper respiratory tract infections, nausea and rash. Grade 3 or higher effects included low white cell blood counts, anemia and diarrhea.
Next steps
Wang believes further investigation of ibrutinib as a first line therapy and in combination with other targeted therapies and traditional cytotoxic agents is essential.
"This drug, which is the safest option we have for MCL, shows unprecedented durable single agent activity," he said. "The favorable toxicity profile also implies that ibrutinib provides the opportunity for less intense and more effective regimens. The long-term impact of ibrutinib definitely warrants further clinical testing."
INFORMATION:
Pharmacyclics, Inc., which developed ibrutinib, sponsored the clinical trial.
Wang's co-authors at MD Anderson include Jorge E. Romaguera, M.D., Liang Zhang, M.D., Ph.D., Kate Newberry, Ph.D., and Zhishuo Ou, M.D., Department of Lymphoma and Myeloma; Lei Li, Ph.D., Department of Experimental Radiation Oncology; and Bingliang Fang, Ph.D., Department of Thoracic and Cardiovascular Surgery.
Other members of the research team include Simon Rule, M.D., Derriford Hospital, Plymouth, United Kingdom; Peter Martin, M.D., Weill Cornell Medical College, New York, New York; Andre Goy, M.D., John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Rebecca Auer, M.D., Ph.D., Barts Health NHS Trust, London, United Kingdom; Brad S. Kahl, M.D., University of Wisconsin, Madison; Wojciech Jurczak, M.D., Ph.D., Jagiellonian University, Krakow, Poland; Ranjana Advani, M.D., Stanford University Medical Center, Stanford, California; Michael E. Williams M.D., University of Virginia School of Medicine, Charlottesville, Virginia; Jacqueline Barrientos, M.D., Department of Medicine, Hofstra North Shore-LIJ, New Hyde Park, New York; Ewa Chmielowska, M.D., Oddzial Kliniczny Onkologii Centrum Onkologii, Bydgoszcz, Poland; John Radford, M.D., The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom; Stephan Stilgenbauer, M.D., Universitatsklinikum Ulm, Klinik fur Innere Medizin II, Ulm, Germany; Martin Dreyling, M.D., Klinikum der Universitat Munchen – Campus Grosshadern, Munich, Germany; Wieslaw Wiktor Jedrzejczak, M.D., Medical University of Warsaw, Poland; Peter Johnson, M.D., Cancer Research UK Centre, University of Southampton, United Kingdom; Stephen E. Spurgeon, M.D., Oregon Health and Science University, Portland, Oregon; Nancy Cheng, M.S., Baylor College of Medicine, Houston, Texas; Jesse McGreivy, M.D., Fong Clow, Sc.D., Joseph Buggy, Ph.D., Betty Chang, Ph.D., Darrin Beaupre, M.D., Ph.D. and Lori A. Kunkel, M.D., Pharmacyclics, Inc., Sunnyvale, CA; and Kristie Blum, M.D., Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
END
Industrial palladium-copper catalysts change their structures before they get to work, already during the activation process. As a result, the reaction is catalysed by a catalyst that is different from the one originally prepared for it. This surprising discovery was made by researchers from the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw.
Removing of nitrates from ground water or chlorine from dry cleaning wastes are important environmental protection operations that require the use of appropriate catalysts. Popular catalysts include well-known ...
LOS ANGELES (June 19, 2013) – In what is believed to be the largest follow-up record of patients with the most common form of hereditary dystonia – a movement disorder that can cause crippling muscle contractions – experts in deep brain stimulation report good success rates and lasting benefits.
Michele Tagliati, MD, neurologist, director of the Movement Disorders Program at Cedars-Sinai Medical Center's Department of Neurology, and Ron L. Alterman, MD, chief of the Division of Neurosurgery at Beth Israel Deaconess Medical Center in Boston, published the study in the ...
(SACRAMENTO, Calif.) — A study of the patients who received injections of steroids contaminated with the fungus Exserohilum rostratum from the New England Compounding Center has found that some patients had fungal infections even though they did not experience a worsening of their symptoms and that magnetic resonance imaging (MRI) can help detect infection, especially among those individuals who received injections from highly contaminated lots.
The study, along with an editorial by UC Davis Assistant Professor of Medical Microbiology and Immunology George R. Thompson, ...
The protected area network in Tanzania is playing a vital role in the survival of savannah bird species as they move west in response to climate and environmental changes, according to new research led by the University of York.
Using data on savannah birds from the Tanzanian Bird Atlas project - which has documented Tanzanian bird distributions over recent decades - the researchers found that they are using protected areas as stepping stones as they move to areas further west where dry seasons are getting longer, with movements of up to 300km noted.
Much debate has centred ...
Electronic components built from single molecules using chemical synthesis could pave the way for smaller, faster and more green and sustainable electronic devices. Now for the first time, a transistor made from just one molecular monolayer has been made to work where it really counts. On a computer chip.
The molecular integrated circuit was created by a group of chemists and physicists from the Department of Chemistry Nano-Science Center at the University of Copenhagen and Chinese Academy of Sciences, Beijing. Their discovery "Ultrathin Reduced Graphene Oxide Films as ...
State policymakers' attention to teacher quality—an issue education research shows is essential to improving schooling outcomes for racial minority students—is highly responsive to low graduation rates among white students, but not to low graduation rates among black students, according to a Baylor University study.
The findings are evidence that "the persisting achievement gap between white and black students has distinctively political foundations," the researchers wrote.
The article, entitled "The Politic Foundations of the Black-White Education Achievement Gap," ...
Piggybacking off the popularity of previous films for the Swim and Black Label collections, LA-based fashion label 'Lauren Elaine' teams up with Unus Lupus Entertainment to present a new brand campaign film, inspired by the 1970's grindhouse genre, for the Lauren Elaine Swim collection. The new film, debuting at the end of June, stars Sabyr Omens, Frances Raye, and Evan Miller, with Adam Powell producing.
"I really wanted to create a sort of sequel to the last Swim collection film, but take it up a notch," says Designer Lauren Elaine. "I wanted to carry ...
Jun 14, 2013 - Softros Systems, Inc. announced Softros LAN Messenger 5.0.3
Softros LAN Messenger became an irreplaceable software in numerous companies. With the help of this messenger you will be able to send files, messages between computers on your employees, sending mass alerts can significantly accelerate your workflows. You can protect your personnel from communicating with friends through Internet messengers, save staff time and protect corporate networks from online attacks via the popular instant messenger (such as Skype, QIP, Yahoo IM).
Softros LAN Messenger ...
As your business grows, there may come a time when your current Montgomery office space is no longer adequate for your company needs and the best solution is to move. Relocating an office is a tedious process and it can be costly as well. If you haven't done the appropriate planning, your business could suffer extensive downtime that could be detrimental to your company's operations and future.
So how does a company remain productive during a Montgomery office move? Proper planning is critical.
1. Plan the Move Well in Advance
You'll need to get your proverbial ...
Who: GadgitKids & Cellular Sales
What: Educational opportunities for individual consumers to learn how to utilize mobile devices to their fullest potential.
When: 9am-3pm; June 22nd; June 29th; July 6th; and July 13th
Where: June 22: 10289 Ulmerton Rd Suite C Largo, FL 33771
June 29: 4430 W. Kennedy Blvd. Tampa, FL 33609
July 6: 6901 22nd Ave. N. Ste 508 St. Petersburg, FL 33710
July 13: 4465 East Bay Dr. Largo, FL 33764
In today's ever evolving technological world, it is easy for mobile device owners to quickly feel overwhelmed by the multitude of ...
